達安基因(002030.SZ):生物工程中心擬繼續參與轉融通證券出借業務 出借數量不超1403.44萬股
格隆匯1月6日丨達安基因(002030.SZ)公佈,近日,公司收到持股5%以上股東廣州生物工程中心有限公司(簡稱“生物工程中心”)出具的《關於繼續參與轉融通證券出借業務的函》(廣金生物函〔2022〕1號),函件主要內容為:
“截至2022年1月6日,生物工程中心通過證券交易所平台出借達安基因股份餘額為729.5萬股,約佔生物工程中心持有達安基因股份總數的3.47%,約佔達安基因總股本的0.52%。鑑於前次轉融通證券出借業務期限即將屆滿,為有效盤活證券資產,生物工程中心擬繼續參與轉融通證券出借業務,將持有的部分達安基因股份出借給中國證券金融股份有限公司,出借股份數量不超過1403.44萬股,不超過達安基因總股本的1.00%,出借期限不超過182天,出借股份的所有權不會發生轉移。”
截至該公吿披露日,生物工程中心通過證券交易所平台出借持有的達安基因股份餘額為729.5萬股,約佔生物工程中心持有達安基因股份總數的3.47%,約佔達安基因總股本的0.52%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.